BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

355 related articles for article (PubMed ID: 16553537)

  • 21. Incidence of adverse events and comparative tolerability of selective serotonin reuptake inhibitors, and serotonin and norepinephrine reuptake inhibitors for the treatment of anxiety, obsessive-compulsive, and stress disorders: a systematic review and network meta-analysis.
    Gosmann NP; Costa MA; Jaeger MB; Frozi J; Spanemberg L; Manfro GG; Cortese S; Cuijpers P; Pine DS; Salum GA
    Psychol Med; 2023 Jul; 53(9):3783-3792. PubMed ID: 37278215
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A longitudinal event-related potential study of selective serotonin reuptake inhibitor therapy in treatment-naïve pediatric obsessive compulsive disorder patients.
    Yamamuro K; Ota T; Iida J; Kishimoto N; Nakanishi Y; Matsuura H; Uratani M; Okazaki K; Kishimoto T
    Psychiatry Res; 2016 Nov; 245():217-223. PubMed ID: 27552672
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of tryptophan depletion on selective serotonin reuptake inhibitor-remitted patients with obsessive compulsive disorder.
    Hood SD; Broyd A; Robinson H; Lee J; Hudaib AR; Hince DA
    J Psychopharmacol; 2017 Dec; 31(12):1615-1623. PubMed ID: 29095069
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A review of the efficacy of selective serotonin reuptake inhibitors in obsessive-compulsive disorder.
    Pigott TA; Seay SM
    J Clin Psychiatry; 1999 Feb; 60(2):101-6. PubMed ID: 10084636
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment outcome of obsessive compulsive disorder with comorbid social phobia.
    Carrasco JL; Hollander E; Schneier FR; Liebowitz MR
    J Clin Psychiatry; 1992 Nov; 53(11):387-91. PubMed ID: 1459968
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Biological dissection of anxiety disorders: the clinical role of selective serotonin reuptake inhibitors with particular reference to fluvoxamine.
    den Boer JA; Westenberg HG; De Leeuw AS; van Vliet IM
    Int Clin Psychopharmacol; 1995 Jan; 9 Suppl 4():47-52. PubMed ID: 7622824
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Selective serotonin re-uptake inhibitors for children and adolescents.
    Ziervogel CF
    Eur Child Adolesc Psychiatry; 2000; 9 Suppl 1():I20-6. PubMed ID: 11140777
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of comorbidity on treatment response to paroxetine in pediatric obsessive-compulsive disorder: is the use of exclusion criteria empirically supported in randomized clinical trials?
    Geller DA; Biederman J; Stewart SE; Mullin B; Farrell C; Wagner KD; Emslie G; Carpenter D
    J Child Adolesc Psychopharmacol; 2003; 13 Suppl 1():S19-29. PubMed ID: 12880497
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Clinical significance of selective serotonin reuptake inhibitor (SSRI) in the treatment of depression].
    Semba J
    Nihon Yakurigaku Zasshi; 2000 Aug; 116(2):79-84. PubMed ID: 10976459
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Citalopram in the treatment of obsessive-compulsive disorder: an open pilot study.
    Koponen H; Lepola U; Leinonen E; Jokinen R; Penttinen J; Turtonen J
    Acta Psychiatr Scand; 1997 Nov; 96(5):343-6. PubMed ID: 9395151
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Placebo response in trials with patients with anxiety, obsessive-compulsive and stress disorders across the lifespan: a three-level meta-analysis.
    Motta LS; Gosmann NP; Costa MA; Jaeger MB; Frozi J; Grevet LT; Spanemberg L; Manfro GG; Cuijpers P; Pine DS; Salum G
    BMJ Ment Health; 2023 Feb; 26(1):. PubMed ID: 37142305
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Impact of Antidepressant Dose and Class on Treatment Response in Pediatric Anxiety Disorders: A Meta-Analysis.
    Strawn JR; Mills JA; Sauley BA; Welge JA
    J Am Acad Child Adolesc Psychiatry; 2018 Apr; 57(4):235-244.e2. PubMed ID: 29588049
    [TBL] [Abstract][Full Text] [Related]  

  • 33. OCD: where the serotonin selectivity story begins.
    Pigott TA
    J Clin Psychiatry; 1996; 57 Suppl 6():11-20. PubMed ID: 8647793
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Secondary outcomes from the pediatric obsessive compulsive disorder treatment study II.
    Conelea CA; Selles RR; Benito KG; Walther MM; Machan JT; Garcia AM; Sapyta J; Morris S; Franklin M; Freeman JB
    J Psychiatr Res; 2017 Sep; 92():94-100. PubMed ID: 28412602
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Obsessions: the impact and treatment of obsessive-compulsive disorder in children and adolescents.
    Thomsen PH
    J Psychopharmacol; 2000; 14(2 Suppl 1):S31-37. PubMed ID: 10888029
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Paroxetine. An update of its pharmacology and therapeutic use in depression and a review of its use in other disorders.
    Gunasekara NS; Noble S; Benfield P
    Drugs; 1998 Jan; 55(1):85-120. PubMed ID: 9463792
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Distinct trajectories of long-term symptom severity in pediatric obsessive-compulsive disorder during and after stepped-care treatment.
    Jensen S; Højgaard DRMA; Hybel KA; Mortensen EL; Skarphedinsson G; Melin K; Ivarsson T; Nissen JB; Weidle B; Valderhaug R; Torp NC; Dahl K; Compton S; Thomsen PH
    J Child Psychol Psychiatry; 2020 Sep; 61(9):969-978. PubMed ID: 31736082
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Role of selective serotonin reuptake inhibitors in psychiatric disorders: a comprehensive review.
    Vaswani M; Linda FK; Ramesh S
    Prog Neuropsychopharmacol Biol Psychiatry; 2003 Feb; 27(1):85-102. PubMed ID: 12551730
    [TBL] [Abstract][Full Text] [Related]  

  • 39. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders - first revision.
    Bandelow B; Zohar J; Hollander E; Kasper S; Möller HJ; ; Zohar J; Hollander E; Kasper S; Möller HJ; Bandelow B; Allgulander C; Ayuso-Gutierrez J; Baldwin DS; Buenvicius R; Cassano G; Fineberg N; Gabriels L; Hindmarch I; Kaiya H; Klein DF; Lader M; Lecrubier Y; Lépine JP; Liebowitz MR; Lopez-Ibor JJ; Marazziti D; Miguel EC; Oh KS; Preter M; Rupprecht R; Sato M; Starcevic V; Stein DJ; van Ameringen M; Vega J
    World J Biol Psychiatry; 2008; 9(4):248-312. PubMed ID: 18949648
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Where are we going with SSRIs?
    Isaac M
    Eur Neuropsychopharmacol; 1999 Jul; 9 Suppl 3():S101-6. PubMed ID: 10523065
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.